No description available.

Thesis (M. Phil.)--University of Hong Kong, 2002. / Includes bibliographical references (leaves 166-207).

Thesis (M.Nurs.)--University of Hong Kong, 2004. / Also available in print.

Made available in DSpace on 2014-06-11T19:31:08Z (GMT). No. of bitstreams: 0 Previous issue date: 2012-02-10Bitstream added on 2014-06-13T19:20:09Z : No. of bitstreams: 1 mostachio_gq_dr_jabo.pdf: 1264077 bytes, checksum: 8bcdd5ff1f9b2ceba2b78fb1998b3095 (MD5) / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) / A hiperplasia prostática benigna (HPB) tem início no animal com um a dois anos de idade, no entanto, sua fisiopatologia não está totalmente compreendida. O objetivo principal do tratamento da HPB é controlar o crescimento do órgão, prevenir complicações e efeitos colaterais. Desta maneira, o efeito da toxina botulínica tem sido investigado, mostrando bons resultados no homem. Com base nisso, este estudo objetivou fornecer informações acerca dos efeitos da finasterida e da TB-A no tratamento da HPB canina. Para tanto, 24 cães adultos foram divididos aleatoriamente em quatro grupos e submetidos à administração de solução fisiológica 0,9%, 5 mg de finasterida, 500 U de TB-A ou 500 U de TB-A associada a finasterida, e avaliados durante 16 semanas. Complicações locais ou alterações sistêmicas não foram observadas nos animais pertencentes aos grupos experimentais. Após 16 semanas da administração de 5 mg de finasterida o volume prostático reduziu 45,3% e ocorreu um aumento de 5 vezes nas taxa de morte celular. Comparando-se os valores do volume prostático após 16 semanas da aplicação de 500 U de TB-A ou 500 U de TB-A associada a finasterida com os valores basais, observamos uma redução de 30,9 e 51,3%, respectivamente. Neste mesmo período, ocorreu um aumento de seis e oito vezes da taxa de apoptose nos animais do grupo III e IV. Os resultados sugerem que os três protocolos terapêuticos promovem significativa redução do volume prostático e esta se deve a apoptose celular ao invés de necrose. Desta forma, o presente ensaio contribui de forma singular e inovadora para o conhecimento dos efeitos desta nova modalidade de tratamento na HPB canina / Benign prostatic hyperplasia (BPH) starts the development in animals aging about 1 – 2 years, however, its pathophysiology is not fully elucidated. The main goal of BPH is to control the growth of the prostate, to prevent complications, and to minimize the adverse effects. Thus, the effect of botulinum toxin A (BT-A) has been investigated in humans with good results. Based on that, this study aimed to provide information about the effects of finasteride and BT-A in the treatment of BPH in dogs. For that, 24 adults dogs were randomly divided in four groups and submitted to administration of saline solution, 5 mg of finasteride, 500 of BT-A or 500 U of BT-A associated with finasteride, and evaluated along 16 weeks. Local complications and systemic effects were not observed. After 16 weeks of the application of 5 mg of finasteride the prostatic volume decreased 45,3% and occurred a 5-fold increased in the rate of cell death. Comparing the values of the prostatic volume after 16 weeks of administration of 500 U of BT-A or 500 U BT-A associated with finasteride with the baseline, a decrease of 30,9 and 51,3% were observed, respectively. In the same period, a increase of 6 and 8 times occurred in the rate of apoptosis in the animals of group III and IV. The results suggest that all 3 treatments protocols further significant reduction in the prostate volume have shown to significantly reduce the volume of prostate, and this reduction is due apoptosis instead necrosis. This way, the present study is an innovative and singular contribution for the knowledge of the effects of BT-A on canine prostate

Thesis (Ph. D.)--Ohio State University, 2006. / Title from first page of PDF file. Includes bibliographical references (p. 87-93).

Thesis (M.S.)--West Virginia University, 2000. / Title from document title page. Document formatted into pages; contains ix, 154 p. : ill. Includes abstract. Includes bibliographical references (p. 137-143).

No description available.

Orientador: Wilter Ricardo Russiano Vicente / Banca: Aracélle Elisane Alves / Banca: Fabiana Ferreira de Souza / Banca: Maria Denise Lopes / Banca: Maricy Apparicio Ferreira / Resumo: A hiperplasia prostática benigna (HPB) tem início no animal com um a dois anos de idade, no entanto, sua fisiopatologia não está totalmente compreendida. O objetivo principal do tratamento da HPB é controlar o crescimento do órgão, prevenir complicações e efeitos colaterais. Desta maneira, o efeito da toxina botulínica tem sido investigado, mostrando bons resultados no homem. Com base nisso, este estudo objetivou fornecer informações acerca dos efeitos da finasterida e da TB-A no tratamento da HPB canina. Para tanto, 24 cães adultos foram divididos aleatoriamente em quatro grupos e submetidos à administração de solução fisiológica 0,9%, 5 mg de finasterida, 500 U de TB-A ou 500 U de TB-A associada a finasterida, e avaliados durante 16 semanas. Complicações locais ou alterações sistêmicas não foram observadas nos animais pertencentes aos grupos experimentais. Após 16 semanas da administração de 5 mg de finasterida o volume prostático reduziu 45,3% e ocorreu um aumento de 5 vezes nas taxa de morte celular. Comparando-se os valores do volume prostático após 16 semanas da aplicação de 500 U de TB-A ou 500 U de TB-A associada a finasterida com os valores basais, observamos uma redução de 30,9 e 51,3%, respectivamente. Neste mesmo período, ocorreu um aumento de seis e oito vezes da taxa de apoptose nos animais do grupo III e IV. Os resultados sugerem que os três protocolos terapêuticos promovem significativa redução do volume prostático e esta se deve a apoptose celular ao invés de necrose. Desta forma, o presente ensaio contribui de forma singular e inovadora para o conhecimento dos efeitos desta nova modalidade de tratamento na HPB canina / Abstract: Benign prostatic hyperplasia (BPH) starts the development in animals aging about 1 - 2 years, however, its pathophysiology is not fully elucidated. The main goal of BPH is to control the growth of the prostate, to prevent complications, and to minimize the adverse effects. Thus, the effect of botulinum toxin A (BT-A) has been investigated in humans with good results. Based on that, this study aimed to provide information about the effects of finasteride and BT-A in the treatment of BPH in dogs. For that, 24 adults dogs were randomly divided in four groups and submitted to administration of saline solution, 5 mg of finasteride, 500 of BT-A or 500 U of BT-A associated with finasteride, and evaluated along 16 weeks. Local complications and systemic effects were not observed. After 16 weeks of the application of 5 mg of finasteride the prostatic volume decreased 45,3% and occurred a 5-fold increased in the rate of cell death. Comparing the values of the prostatic volume after 16 weeks of administration of 500 U of BT-A or 500 U BT-A associated with finasteride with the baseline, a decrease of 30,9 and 51,3% were observed, respectively. In the same period, a increase of 6 and 8 times occurred in the rate of apoptosis in the animals of group III and IV. The results suggest that all 3 treatments protocols further significant reduction in the prostate volume have shown to significantly reduce the volume of prostate, and this reduction is due apoptosis instead necrosis. This way, the present study is an innovative and singular contribution for the knowledge of the effects of BT-A on canine prostate / Doutor

by Kin-mang Lau. / Thesis (M.Phil.)--Chinese University of Hong Kong, 1994. / Includes bibliographical references (leaves 148-167). / Chapter I --- ABSTRACT --- p.1 / Chapter II --- INTRODUCTION --- p.3 / Chapter II. 1 --- Epidemiology of prostate cancer --- p.3 / Chapter II.2 --- Anatomy of the human prostate --- p.13 / Chapter II.3 --- Pathology of prostate diseases --- p.14 / Chapter II.3.1 --- Prostatic Hyperplasia / Chapter II.3.2 --- Atypical Hyperplasia / Chapter II.3.3 --- Prostatic Carcinoma / Chapter II.4 --- Tumour Suppressor Gene - Human p53 --- p.19 / Chapter II.4.1 --- General aspects / Chapter II.4.2 --- Human p53 gene - Historical perspectives / Chapter II.4.3 --- Human p53 gene - Structure / Chapter II.4.4 --- Human p53 protein - Structure / Chapter II.4.5 --- Wild-type p53 protein - Biochemical functions / Chapter II.4.6 --- Wild-type p53 protein - Biological function / Chapter II.4.7 --- Regulation of p53 function / Chapter II.4.8 --- p53 mutations in Human cancers / Chapter II.4.9 --- Properties of mutant p53 protein / Chapter II.5 --- Human Papillomavirus (HPV) --- p.38 / Chapter II.5.1. --- Virion Structure / Chapter II.5.2 --- Classification / Chapter II.5.3. --- Papillomaviruses in Human Cancers / Chapter II.5.4. --- Relationship between p53 alteration and HPV infection / Chapter II.6 --- p53 alteration and Prostate cancers --- p.42 / Chapter II.6.1. --- Cytogenetic studies / Chapter II.6.2. --- Hybridization analysis / Chapter II.6.3. --- p53 alterations and Prostatic cell lines / Chapter III. --- OBJECTIVES OF STUDY --- p.46 / Chapter IV --- MATERIALS & METHODS --- p.47 / Chapter IV.1 --- Patients and Materials --- p.47 / Chapter IV.2 --- Histological Grading --- p.47 / Chapter IV.2.1 --- Gleason grading / Chapter IV.2.2 --- W.H.O. grading (Mostofi) / Chapter IV.3 --- Staging of Prostatic carcinoma --- p.48 / Chapter IV.4 --- Collection of Blood and Tissue samples --- p.49 / Chapter IV.5 --- Immunohistochemical studies of Prostatic lesions --- p.50 / Chapter IV.5.1 --- Antibodies used / Chapter IV.5.2 --- Methods in frozen sections / Chapter IV.5.3 --- Methods in paraffin sections / Chapter IV.5.4 --- Controls / Chapter IV.5.5 --- Immunohistochemical evaluation / Chapter IV.6 --- Extraction of DNA from tissues and blood samples --- p.52 / Chapter IV.6.1 --- Extraction of genomic DNA from blood / Chapter IV.6.2 --- Extraction of genomic DNA from tissue / Chapter IV.7 --- Hybridization analysis --- p.54 / Chapter IV.7.1 --- Preparation of Cloned Probe DNA / Chapter IV.7.2 --- Transformation of CaCl2-treated competent cell / Chapter IV.7.3 --- Cultures of Transformants / Chapter IV.7.4 --- Isolationof plasmid DNA from transformant cultures / Chapter IV.7.5 --- Purification of DNA Probe by electroelution / Chapter IV.7.6 --- Radioactive labelling of DNA Probes / Chapter IV.7.7 --- Purification of radioactive labelled DNA Probes / Chapter IV.7.8 --- Southern Blotting Technique / Chapter IV.7.9 --- Hybridization of DNA Blots with labelled DNA Probe / Chapter IV.8 --- Polymerase Chain Reaction - Single Stranded Conformational Polymorphism (PCR-SSCP) --- p.63 / Chapter IV.8.1 --- 5'-radioactive labelling of primer / Chapter IV.8.2 --- Amplification of target sequence by PCR / Chapter IV.8.3 --- Nondenaturing Polyacrylamide Gel Electrophoresis / Chapter IV.8.4 --- Direct DNA sequencing of PCR products with p53 mutation / Chapter IV.8.5 --- Controls / Chapter IV.9 --- PCR method for detection of Human Papillomavirus (HPV) --- p.71 / Chapter IV.9.1 --- PCR-Amplification / Chapter IV.9.2 --- DNA alkali Blotting Technique / Chapter IV.9.3 --- Preparation of Radioactive labelled Oligoprobes / Chapter IV.9.4 --- Hybridization of DNA Blots with radioactive labelled Oligoprobes / Chapter IV.9.5 --- Controls / Chapter IV.9.6 --- Sensitivity of HPV 18 detection by PCR / Chapter V --- RESULTS --- p.76 / Chapter V.1 --- Grading and Staging of patients with prostatic carcinoma --- p.76 / Chapter V.2 --- Immunohistochemistry in prostatic lesions --- p.80 / Chapter V.3 --- Results of hybridization analysis --- p.81 / Chapter V.4 --- PCR-SSCP findings in prostatic hyperplasia and carcinoma --- p.97 / Chapter V.5 --- PCR detection of HPV in human prostate --- p.110 / Chapter VI --- DISCUSSION --- p.125 / Chapter VII --- CONCLUSION --- p.146 / Chapter VIII --- REFERENCES --- p.148 / Chapter IX --- APPENDIX --- p.168 / Chapter X --- ACKNOWLEDGEMENT --- p.172

by Yu Hon Ming. / Thesis (M.Sc.)--Chinese University of Hong Kong, 1996. / Includes bibliographical references (leaves 70-74). / Abstract --- p.ii / Acknowledgements --- p.v / Abbreviations --- p.vi / List of tables and figures --- p.viii / Chapter Chapter I. --- Introduction / Chapter 1. --- Background --- p.1 / Chapter 2. --- Physiology of prostate --- p.3 / Chapter 2.1. --- Prostate --- p.3 / Chapter 2.2. --- Embryonic development of prostate --- p.3 / Chapter 2.3. --- Anatomy of prostate --- p.5 / Chapter 2.4. --- The role of steroids in the growth of prostate --- p.7 / Chapter 2.4.1. --- T --- p.7 / Chapter 2.4.2. --- DHT --- p.8 / Chapter 2.5. --- 5α-reductase --- p.10 / Chapter 3. --- Pathophysiology of BPH --- p.11 / Chapter 3.1. --- Anatomic progression of BPH --- p.11 / Chapter 3.2. --- Epidemiology of BPH --- p.11 / Chapter 3.3. --- Pathogenesis of BPH --- p.12 / Chapter 3.4. --- Clinical manifestations of BPH --- p.13 / Chapter 3.5. --- Diagnosis of BPH --- p.14 / Chapter 4. --- Treatment of BPH --- p.15 / Chapter 4.1. --- a-adrenergic antagonist --- p.16 / Chapter 4.2. --- DHT hypothesis --- p.16 / Chapter 4.3. --- 5α-reductase inhibitor --- p.17 / Chapter 5. --- Radioimmunoassay of DHT --- p.21 / Chapter 6. --- Objectives --- p.22 / Chapter Chapter II. --- Materials and methods --- p.23 / Chapter 1. --- Materials and methods for development of specific RIA for serum DHT --- p.23 / Chapter 1.1. --- Materials --- p.23 / Chapter 1.2. --- Methods --- p.23 / Chapter 1.2.1. --- Antiserum for DHT-RIA --- p.23 / Chapter 1.2.1.1. --- Optimal antibody titre and dilution curve for DHT-RIA --- p.24 / Chapter 1.2.1.2. --- Cross-reactivity with related steroids --- p.25 / Chapter 1.2.2. --- KMnO4 treatment of T antiserum for DHT-RIA --- p.26 / Chapter 1.2.2.1. --- Optimization of KMnO4 treatment --- p.26 / Chapter 1.2.2.2. --- Upper limit of oxidizing power of 0.5% KMnO4 --- p.27 / Chapter 1.2.2.3. --- Efficiency and background effect of 0.5% KMnO4 oxidation on DHT-RIA --- p.28 / Chapter 1.2.3. --- Characteristic of DHT-RIA --- p.29 / Chapter 1.2.3.1. --- Standard preparation --- p.29 / Chapter 1.2.3.2. --- Blank preparation --- p.30 / Chapter 1.2.3.3. --- Control preparation --- p.31 / Chapter 1.2.3.4. --- Sample preparation --- p.31 / Chapter 1.2.3.5. --- Dextran-coated charcoal --- p.31 / Chapter 1.2.3.6. --- DHT-RIA procedure --- p.32 / Chapter 1.2.3.7. --- Sensitivity test for DHT-RIA --- p.33 / Chapter 1.2.3.8. --- Linearity test for DHT-RIA --- p.33 / Chapter 1.2.3.9. --- Recovery test for DHT-RIA --- p.34 / Chapter 1.2.3.10. --- Precision test for DHT-RIA --- p.34 / Chapter 2. --- Materials and methods for establishing reference range of DHT in Chinese males and females --- p.35 / Chapter 2.1. --- Samples --- p.35 / Chapter 2.2. --- Methods --- p.35 / Chapter 2.2.1. --- DHT determination --- p.35 / Chapter 2.2.2. --- T determination --- p.36 / Chapter 2.2.3. --- Cholesterol determination --- p.37 / Chapter 3. --- Materials and methods for a small clinical trial on the usefulness of 5α-reductase inhibitor (finasteride) in the treatment of BPH --- p.38 / Chapter 3.1. --- Samples --- p.38 / Chapter 3.2. --- Methods --- p.38 / Chapter 4. --- Statistical analysis --- p.39 / Chapter Chapter III. --- Result --- p.40 / Chapter 1. --- DHT-RIA --- p.40 / Chapter 1.1. --- Antiserum for DHT-RIA / Chapter 1.1.1. --- Optimal antibody titre for DHT-RIA --- p.40 / Chapter 1.1.2. --- Cross reactivity with related steroids --- p.42 / Chapter 1.2. --- KMnO4 treatment of T antiserum for DHT-RIA --- p.43 / Chapter 1.2.1. --- Optimization of KMnO4 treatment --- p.43 / Chapter 1.2.2. --- Upper limit of oxidizing power of 0.5% KMnO4 --- p.44 / Chapter 1.2.3. --- Efficiency and background effect of 0.5% KMnO4 treatment on DHT-RIA --- p.45 / Chapter 1.3. --- Characterization of the DHT-RIA --- p.47 / Chapter 2. --- Reference range for DHT in Chinese males and females --- p.51 / Chapter 2.1. --- Reference range of DHT in three different study groups --- p.51 / Chapter 2.2. --- Ratio of DHT/T in Chinese males and Caucasian males --- p.52 / Chapter 2.3. --- Correlation studies --- p.53 / Chapter 3. --- Results of small clinical trial --- p.54 / Chapter 3.1. --- Mean serum analyte changes during the course --- p.54 / Chapter 3.2. --- Changes in analyte concentrations during the course --- p.56 / Chapter 3.3. --- Difference in mean serum analytes between BPH males predose level and normal males with and without age matching --- p.57 / Chapter 3.4. --- "The response, percentage change of DHT and DHT/T ratio of individual patient during the course of study" --- p.58 / Chapter Chapter IV. --- Discussion --- p.59 / Chapter 1. --- Radioimmunoassay for DHT --- p.59 / Chapter 2 . --- Establishment of DHT reference range in Chinese males and females --- p.62 / Chapter 3. --- The usefulness of 5a reductase inhibitor in the treatment of BPH --- p.65 / Chapter Chapter V. --- Conclusion --- p.69 / References --- p.70